首页> 美国卫生研究院文献>The British Journal of Cancer. Supplement >Advanced lymphosarcoma treated by total body irradiation.
【2h】

Advanced lymphosarcoma treated by total body irradiation.

机译:全身照射治疗晚期淋巴肉瘤。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Twenty-five cases of clinical Stage III and Stage IV lymphosarcoma primarily treated by total body irradiation (TBI) are reported. Fifteen cases demonstrated nodular histology and 10 demonstrated diffuse histology by the Rappaport criteria. Treatments were 15 rad given twice weekly, calculated to midpelvis, to a total dose of 150 rad. Toxicity was confined to thrombocytopenia, one-third of patients requiring interruptions in the treatment course to allow platelet count recovery. Five patients had additional local irradiation. Complete responses were seen in 80% of patients and partial responses in 20%. Sixteen patients (64%) have been in continuous, unmaintained remission since treatments for variable periods to 39 months. Of 9 patients with clinically recurrent disease, 3 received further TBI and are in remission, 3 are in remission on chemotherapy, one patient has died, failing on all therapy, and 2 have not been treated. One patient died of pneumonia at 12 months, without clinical evidence of disease. Overall, actuarial survival is 87% at 2 years and compares well with survival in a sequential combination drug treated group of patients matched for age, sex, and histology, though differences are not statistically significant in these small groups. Total body irradiation is an effective systemic agent in the management of advanced lymphosarcoma and should be considered in treating this disease.
机译:据报道,有25例主要通过全身照射(TBI)治疗的临床III期和IV期淋巴肉瘤病例。根据Rappaport标准,有15例表现出结节性组织学,有10例表现出弥散性组织学。按照骨盆中段计算,每周两次接受15拉德的治疗,总剂量为150拉德。毒性仅限于血小板减少症,三分之一的患者需要中断治疗过程以恢复血小板计数。五名患者接受了额外的局部照射。在80%的患者中可以看到完全缓解,在20%的患者中可以看到部分缓解。自治疗至39个月不等期间以来,已有16例患者(64%)持续持续缓解。在9例临床复发性疾病患者中,有3例接受了进一步的TBI缓解,3例因化疗而缓解,1例死亡,所有治疗均无效,2例未接受治疗。 1名患者在12个月时死于肺炎,而没有临床证据显示疾病。总体而言,精算生存率在2年时为87%,与按年龄,性别和组织学相匹配的顺序联合药物治疗组的生存率比较,尽管在这些小群体中差异无统计学意义。全身照射是治疗晚期淋巴肉瘤的有效全身药物,在治疗该疾病时应予以考虑。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号